An important limitation of recombinant adeno-associated virus (rAAV) vector efficiency is the requirement of hostcell-mediated synthesis of double-stranded DNA from the single-stranded genome. We have bypassed this step in a specialized self-complementary rAAV (scAAV) vector, by utilizing the tendency of AAV to package DNA dimers when the replicating genome is half the length of the wild type (wt). To produce these vectors efficiently, we have deleted the terminal resolution site (trs) from one rAAV TR, preventing the initiation of replication at the mutated end. These constructs generate single-stranded, inverted repeat genomes, with a wt TR at each end, and a mutated TR in the middle. After uncoating, the viral DNA folds through intramolecular base pairing within the mutant TR, which then proceeds through the genome to form a double-stranded molecule. We have used the scAAV to investigate barriers to rAAV transduction in the mouse liver, muscle and brain. In each tissue, scAAV was characterized by faster onset of gene expression and higher transduction efficiency. This study confirms earlier predictions that complementary-strand DNA synthesis is the primary barrier to rAAV-2 transduction. The scAAV is unaffected by this barrier, and provides an extremely efficient vector for gene transfer into many types of cells in vivo.
Introduction
Adeno-associated virus (AAV), and gene delivery vectors derived from it, package a single-stranded DNA (ssDNA) genome. Palindromic terminal repeat (TR) structures at each end of the genome serve as primers for host-cell-mediated synthesis of the complementary DNA strand after infection. We have bypassed this step by packaging both strands of an rAAV genome as an inverted repeat, ssDNA molecule. This unique structure allows an intramolecular base-pairing reaction to generate the double-stranded DNA template for gene expression, in the absence of DNA synthesis in the target cell. 1 However, we expect that the conformational constraints of DNA packaging in parvoviruses most likely preclude the double-stranded structure, while the DNA is contained within the capsid. 2 Further, the packaging of AAV DNA is dependent on an active viral helicase function, which also suggests that the DNA is single stranded as it enters the capsid. 3 The requirement for complementary-strand synthesis, or recruitment by base pairing with a coinfecting complementary genome, is an important limiting step in rAAV transduction, which severely reduces its efficiency in many cell types. [4] [5] [6] Transduction by AAV-2 in mouse liver is only 1-5% at a dose where vector DNA can be detected in most of the hepatocytes. 7 This vector DNA can be activated by coinfection with the adenovirus, which promotes complementary-strand synthesis. 8 This suggests that the greatest barrier to rAAV transduction of the liver tissue is the conversion of singlestranded virion DNA to duplex, and that the scAAV vector will not suffer from this limitation.
This prediction was supported in a mouse liver transduction experiment comparing an scAAV vector with a conventional rAAV vector. 1 The scAAV vector yielded a faster onset and higher level gene expression than the cognate ssAAV vector. A recent report has corroborated the efficiency of the scAAV vector in mouse retinal pigmented epithelium, where higher levels of transduction and faster onset were also reported. 9 In this report, we demonstrate the enhanced transduction potential of the scAAV vector in the liver and other tissues. A single injection of scAAV results in 25-50% transduction of liver cells. Injections into the muscle and brain result in higher level transductions at lower doses than the conventional rAAV vector. Additionally, we have created a specialized rAAV vector plasmid which efficiently generates the scAAV vector, rather than mixed populations of particles containing varying amounts of monomeric genomes.
Results

Mutant vectors for efficient production of scAAV vectors
To streamline the production of scAAV vector stocks, and eliminate the complications of mixed populations of dimer and monomer genomes, we have created a mutant vector construct to generate the dimer genomes. In this construct, the terminal resolution site (trs), from which rolling hairpin replication initiates, is deleted from one TR (Figure 1a) . The other TR is wild type (wt). The effect is that the replication fork initiates from the wt end of the genome, proceeds through the mutant end without terminal resolution, and then continues back across the genome, using the opposite strand as a template, to create the dimer. The product is a self-complementary genome with the mutant TR in the middle, and wt TRs at each end. Replication and packaging of progeny from the self-complementary replicative-form molecule then proceed as normal from the two wt TRs. The dimeric inverted repeat structure is maintained through each round of replication, and the mutation in the middle TR prevents the dimer genome from being processed back to the monomer form by the AAV Rep protein. Importantly, during vector production, both ends of the rAAV vector sequence can still be rescued from the transfected plasmid. The palindromic regions, 'B', 'C', and most of 'A', which mediate this event independently of the trs, are left intact.
We generated vector stocks using this mutant background (Figure 1b) , and fractionated the products on CsCl gradients. The fractions were analyzed by alkaline agarose gel electrophoresis (Figure 1c ). These constructs consistently produce 90-95% scAAV vectors. A Hirt extract of low molecular weight DNA from the vector-producing cells shows that virtually all the replicating DNA is in dimeric, or larger multimeric molecules (Figure 1c , Hirt). These mutant TR constructs yielded greater amounts of scAAV vector, and allowed the use of iodixanol/heparin for the purification of these vectors, without the additional step of CsCl density separation. Vectors made from these plasmids transduce with the same efficiency as scAAV made from conventional constructs with two wt TRs, with efficiencies between 5 and 25 transducing units per DNA-containing particle (data not shown).
Time course and dose-response of scAAV expression in the muscle
The efficiency of the scAAV vector was compared to a single-strand rAAV in vivo, through a dose-response experiment in the mouse muscle. The scAAV comprised a CMV promoter, transcribing the mouse erythropoietin (mEpo) cDNA sequence. This was compared to the identical transgene in a conventional rAAV construct containing a stuffer fragment to prevent packaging of dimer genomes. Vector genome-containing particles were quantified by both dot blot and Southern blotting of alkaline agarose gels. Since each scAAV vector particle contains two copies of the genome, the particle numbers were normalized by dividing the scAAV genome copies by two. The indicated number of particles of each vector was injected directly into mouse right hind limb gastrocnemius/soleus muscle complex (n¼3), and the mice were bled at 1-4-week intervals to measure the elevation in hematocrit, as a functional endpoint measure of mEpo expression (Figure 2 ). The greatest kinetic difference between the two vectors was observed at the highest dose, between days 7 and 14 postinjection (PI). This reflects transgene expression during days 1-9 PI, considering the lag in production of red blood cells in response to increased mEpo expression. As predicted, the rise time in response to the scAAV is far shorter, elevating hematocrit from a baseline of 50% to approximately 70% by 14 days PI. In contrast, the conventional rAAV vector raised the hematocrit to an average of 56% over the same period. By 49 days PI, all of the animals receiving the highest dose of scAAV had died from complications of polycythemia (eg stroke).
At the lower vector doses, there were also clear differences between the two vectors. The minimal doses to induce observable elevations in hematocrit were 5 Â 10 8 for the scAAV vector, and 5 Â 10 9 for the conventional vector. Surprisingly, the hematocrit of the scAAVmEpo-treated mice continued to rise through a period of up to 79 days PI at intermediate vector doses. We expected the hematocrit to reach a stable plateau within the first few weeks, or just enough time for the mice to respond to the level of Epo being expressed immediately after uptake of the vector. This suggested that either there was an additional lag in transport of the vector to the nucleus and/or uncoating, or that further modifications to the double-stranded vector DNA are occurring over time, such as circularization or amplification, which may influence transgene expression. Nevertheless, the two predicted properties of the scAAV vectors, faster onset of expression and higher transducing efficiency, were confirmed.
Direct visualization of liver cell transduction
We had previously shown higher levels of vector expression in the liver tissue, using scAAV vectors expressing the mEpo gene. While this was consistent with greater numbers of liver cells being transduced, a direct assessment of vector gene expression was not possible with the mEpo reporter. In order to directly visualize the number of hepatocytes transduced with scAAV vectors in vivo, a TR mutant construct ( Figure 1a ) was modified to express eGFP from a liver-specific promoter (LSP). This plasmid, p-trsLSP-GFP (Figure 1b) , generated the scAAV vector. A second construct, pTRdSM-LSP-GFP, included two wt TRs and part of a neo gene, and packaged only dimeric genomes.
Virus from each construct was purified by heparin agarose chromatography, and 5 Â 10 10 virus particles of each were delivered to the adult mouse liver by tail vein injection. Representative liver sections were evaluated for GFP expression at 6 weeks PI (Figure 3a ). The few GFP-positive cells from the conventional vector are consistent with previous reports of less than 5% tranduction of hepatocytes at this dose. The 6-week time point was chosen to allow the conventional rAAV to reach the maximum transduction level. In contrast, animals injected with the scAAV vector show GFP TR mutant for self-complementary AAV DM McCarty et al fluorescence in 25-50% of the hepatocytes. Transduction levels in this range had previously only been observed when rAAV-treated mice were coinfected with adenovirus to promote complementary-strand synthesis. Here, we have achieved efficient transduction with a single dose of scAAV which is stable for at least 3 months (data not shown).
Varying doses of the scAAV LSP-GFP vector, ranging from 1.2 Â 10 9 to 2 Â 10 10 particles, were injected into adult mice, and GFP fluorescence was evaluated at These experiments confirm that complementary-strand synthesis is a significant limiting factor in hepatocyte transduction with rAAV vectors, and that this limitation can be overcome with the scAAV vector.
Transduction in brain
The efficiency of scAAV in the central nervous system (CNS), versus the analogous single-stranded vector, was compared using CMV-eGFP reporters. Doses of 2 Â 10 8 and 5 Â 10 8 vector particles were directly injected into the thalamus and ventricle, respectively. In both cases, the animals were killed at 4 weeks PI, and vibrotome sections (50 mm) were evaluated for eGFP expression. Serial sections from scAAV-and ssAAV-treated animals were compared to determine the distribution and efficiency of transduction (Figure 4a and b) . All the four mice in each experimental group showed the same transduction patterns and efficiencies. The distances of detectably transduced cells from the injection point were similar for single-stranded and scAAV vectors, about 3.5 mm. However, the intensity of GFP fluorescence, and the number of fluorescing cells within that radius, was markedly different. This suggested that a far greater number of the scAAV particles within the bolus gave rise to actively expressing vector DNA templates. Similarly, when the scAAV vector was injected into the third ventricle of the mouse, transduced cells were observed in many regions of the brain, both in the ependymal cells lining the ventricles, and within the brain tissue ( Figure  4c and d) . The mice injected with the ssAAV vector into the ventricle showed only a few scattered transduced cells.
Discussion
We have described a mutant AAV vector construct which generates primarily dimeric inverted repeat forms of the genome. These are efficiently packaged to produce scAAV vectors, which have desirable transduction properties such as high efficiency and independence from target-cell DNA synthesis. The advantage of using the mutant construct is that greater than 90% of the 
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vector produced contains the dimer genome. In contrast, rAAV constructs that contain two wt TRs, but are small enough to be packaged as dimers, produce mixed populations of vectors containing dimer genomes and either one or two monomer genomes per vector particle, with varying and largely unpredictable efficiency. 1, 10, 11 While the dimer particles can be separated from those containing single monomer genomes by virtue of their differing densities, they cannot be separated from particles containing two monomer genomes, their densities being nearly equal. The use of the mutant TR construct greatly simplifies production and purification of scAAV vectors. The small amount of monomeric vector genome produced from the mutant TR construct (5-10%) might arise either through rare instances of gene conversion between the wt and mutant TR ends, or through low levels of aberrant resolution of the mutant TR. Efficient gene conversion between the mutant and wt TR is inhibited because the deletion extends to the unique transgene sequence (Figure 1a ), such that homologous sequences do not flank the trs site, thus precluding double-crossover recombinations. There are two ways to take advantage of the increased transduction from scAAV vectors. One is simply to transduce more cells at a given dose; the other is to achieve the same level of expression as ssAAV, but at a lower dose. This is demonstrated in our muscle delivery experiment using the mEpo gene as a reporter. The scAAV-Epo vector required only 5 Â 10 8 particles to produce a significant rise in hematocrit, while the cognate single-stranded vector required 10-fold more particles for a detectable response. As we had previously observed, the scAAV vector also leads to more rapid expression. The ability to reach therapeutic expression levels using a lower vector dose impacts both safety and production concerns. This is particularly true where the delivery volume is limiting, such as in direct injection to the retina, or into the CNS tissue.
The efficacy of the scAAV vector in the CNS is illustrated by our direct injections into the thalamus and ventricle. A relatively low dose of vector (2 Â 10 8 particles in the thalamus) achieved a saturating level of transduction near the point of injection, while the ssAAV at the same dose yielded only sporadic transduced cells. This ability to saturate an area of tissue with vector expression will be important in therapies for some neurodegenerative diseases, or in situations where the high level of transgene expression within a cell may be toxic. Thus, it may be advantageous to produce a modest amount of transgene product in a great number of cells, rather than highly overexpressing the product in a small number of cells. Although we have not characterized the transduced cell population in the CNS, morphologically, they appear to include mostly neurons in the intrathalamic injection, and neurons, glial cells, and ependymal TR mutant for self-complementary AAV DM McCarty et al cells in the intraventricular injection. However, this assay is biased toward cells in which the CMV promoter is active, and may favor neurons over other cell types such as oligodendrocytes. 12, 13 We have also used the scAAV vectors to investigate the limits of rAAV transduction in the liver. Previous studies have shown that hepatocytes are not efficiently transduced by rAAV, the limiting factor apparently being the conversion of the single-stranded vector DNA to duplex by the liver cells. In doses sufficient to deliver rAAV DNA to nearly all of the hepatocytes in the liver, only 1-5% were transduced using single-stranded AAV vectors. In contrast, the scAAV vector transduced an estimated 25-50% of the liver cells at similar doses. This confirms the view that complementary-strand synthesis, or recruitment through intermolecular base pairing, is indeed an important limiting step in rAAV transduction, and further, that the scAAV vectors bypass this step. While this is probably the most significant barrier to rAAV transduction, additional gains may be achieved by delivering the scAAV vector via portal vein, rather than tail vein, thus delivering more vector to the liver rather than distributing significant portions of it to other tissues. The use of alternate serotype AAV vectors will result in further gains in liver transduction, with the AAV type-5, type-1 and, more recently, type-8, all having been shown to have greater tropism for this tissue than the type-2 vector used in this study. The same TR mutant constructs used in this study can be packaged into AAV serotype 1-5 capsids efficiently, with no further modification required (data not shown). Since the route of delivery and AAV serotype tropism affect transduction at steps unrelated to complementary-strand synthesis, we predict that the efficiencies thus gained will be multiplied in the context of the scAAV vector genome.
The scAAV vector promises to be a useful genedelivery reagent in vivo, with properties that clearly distinguish it from the parent virus. Though its payload is small (2150 base pairs of unique sequence), there will undoubtedly be significant gene therapy applications that fit into this niche, such as small protein-coding genes, ribozymes, and anti-sense RNA constructs. Perhaps more exciting is the prospect of advancing mammalian genetics by coupling the high efficiency of the scAAV vector to the compact, but powerful, RNA interference (siRNA) technology. This raises the possibility of conducting effective targeted gene knockout experiments in selected tissues of animals at any stage of development.
Methods Plasmids
The TR deletion constructs which were used for the production of scAAV vectors were made in the background of a previously characterized HpaI linker insertion mutation in the AAV TR (pHpa7).
14 The AAV rep and cap sequences were removed from the plasmid by digestion with XbaI, and the ends were filled in using Klenow. The DNA was then cut with HpaI to remove the trs from one TR (Figure 1a) . Complete transgene cassettes were then inserted between the remaining TR sequences by blunt-end ligation to generate the plasmids pHpa-trsSK, containing the CMVeGFP cassette from the previously described plasmid pCMV-GFP, 1 and ptrsLSP-GFP, containing the same eGFP-coding sequence (Clonetech) under the control of a chimeric LSP 15 (AvaINcoI fragment). The plasmid pTRdSM-LSP-GFP, used as an ssAAV control vector in the liver studies, was derived from a SalI-MluI deletion in the neo gene of the previously published pTReGFP plasmid, followed by substitution of the CMV promoter for LSP as described above. The plasmids p43mEpo (a gift from Barry Byrne, University of Florida) and pmEpol, used to produce the scAAV mEpo and ssAAV mEpo vectors, respectively, have been described previously. 1 
Vector production and purification
All of the vectors used in this study were prepared by three-plasmid transfections in 293 cells, using the AAV serotype-2 helper plasmid pACG, the Ad helper plasmid pXX-6, and the relevant rAAV construct, as previously described. 16, 17 Two of the scAAV vectors used in this study, scAAV-LSP-GFP and scAAV-CMV-GFP, were made from the trs deletion mutants described above. The cognate ssAAV vectors for these were made with identical transgene expression cassettes flanked by two wtTRs, and containing stuffer fragments comprising part of the neo gene, to prevent the encapsidation of dimer genomes. Each vector could therefore be purified on iodixanol step gradients and heparin affinity columns (Pharmacia Hi-trap Heparin), as previously described, 18 without any need for separation of the monomer and dimer genome-containing particles. A third vector, scAAV-CMV-mEpo, was made from a conventional rAAV construct (p43mEpo) with two wt TRs, and the dimer-containing fractions were purified on a CsCl density gradient. While the dimer fraction contained a significant portion of monomer genomes (approximately 50%), they were counted as dimer genomes in the titer. Thus, the efficiency of the scAAV-CMV-mEpo vector was deliberately underestimated rather than overestimated. The cognate ssAAV vector for Epo expression contained a l phage DNA stuffer, and could not be packaged as a dimer, but was, however, purified on CsCl for the purpose of this comparison.
After purification, each vector was titered by alkaline agarose electrophoresis and Southern blot analysis of genome size and concentration. The excised rAAV sequences from plasmids were used as molecular weight and concentration standards. For scAAV vectors, a hybridization signal corresponding to two genome copies was counted as one genome-containing particle.
Animals
Normal C57 mice (2-3-month old), used in this study, were bred and maintained in the Laboratory Animal Facility of University of North Carolina at Chapel Hill. All the procedures were approved by IACUC at the university. All care and procedures were in accordance with the Guide for the Care and Use of Laboratory Animals (NHHS Publication No. (NIH) 85-23).
Direct microinjection of AAV vectors into the mouse brain
scAAV2-CMV-GFP, ssAAV2-CMV-GFP, and scAAV5-CMV-GFP viral vectors were delivered into the thalamus or the dorsal third ventricle of normal mice, 2-3-month TR mutant for self-complementary AAV DM McCarty et al old, by direct microinjection. The stereotaxic (KOPF) microinjection was carried out following the previously published technique, 19, 20 using coordinates from the mouse brain atlas of Franklin and Paxinos. 21 The mice were anesthetized with 2.5% avertin (0.38-0.43 mg/g body weight) before the infusion. AAV viral vectors (2 ml; 1 Â 10 11 vector particles/ml) were infused into the right thalamus at a rate of 0.1 ml/min, and 5 ml into the dorsal third ventricle at a rate of 0.5 ml/min, one injection per site per mouse, four mice per experimental group.
At 4 weeks after infusion, the animals were anesthetized with 2.5% avertin, and then perfused transcardially with cold PBS (pH 7.4), followed by 4% paraformaldehyde in phosphate buffer (0.1 M pH 7.4). The entire mouse brain samples were collected and fixed at 41C in 4% paraformaldehyde, for fluorescent microscopy.
Intravenous injections for liver transduction
Varying doses of vector in PBS were injected intravenously via the tail vein, in a volume of 100 ml. At 6 weeks PI, the animals were transfused transcardially, as described above, and the livers were removed. The liver tissue was frozen in embedding compound on dry ice, and 30 mm sections were cut on a cryostat and mounted for fluorescence microscopy.
